Longitudinal study of patients with anti-SAE antibody-positive dermatomyositis: a multicenter cohort study in China

被引:2
|
作者
Zhang, Yingfang [1 ,2 ]
Liu, Lei [3 ]
Duan, Xinwang [4 ]
Pi, Hui [5 ]
Jiang, Lili [5 ]
Li, Jiang [6 ]
Wang, Guochun [1 ,2 ,7 ,8 ]
Shu, Xiaoming [1 ,2 ,7 ,8 ]
机构
[1] Peking Univ, China Japan Friendship Sch Clin Med, Beijing, Peoples R China
[2] China Japan Friendship Hosp, Dept Rheumatol, Key Lab Myositis, Beijing, Peoples R China
[3] Zhejiang Univ, Dept Rheumatol, Affiliated Hosp 2, Sch Med, Zhejiang, Peoples R China
[4] Nanchang Univ, Affiliated Hosp 2, Dept Rheumatol & Immunol, Nanchang, Jiangxi, Peoples R China
[5] Nanchang Med Coll, Jiangxi Prov Peoples Hosp, Affiliated Hosp 1, Dept Rheumatol, Nanchang, Peoples R China
[6] China Japan Friendship Hosp, Dept Lab Med, Beijing, Peoples R China
[7] China Japan Friendship Hosp, Beijing Key Lab Immune Mediated Inflammatory Dis, Beijing, Peoples R China
[8] China Japan Friendship Hosp, Dept Rheumatol, Yinghua East Rd, Beijing 100029, Peoples R China
基金
中国国家自然科学基金;
关键词
anti-SAE antibody; DM; skin rash; cancer; interstitial lung disease; outcome; MODIFIER ACTIVATING ENZYME; IDIOPATHIC INFLAMMATORY MYOPATHIES; MYOSITIS-SPECIFIC AUTOANTIBODIES; CLINICAL-SIGNIFICANCE; JAPANESE PATIENTS; CANCER; ADULT; CLASSIFICATION; IDENTIFICATION; POLYMYOSITIS;
D O I
10.1093/rheumatology/keae232
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To describe the longitudinal study and long-term prognosis of a multicentre large inception cohort of patients with anti-SAE positive DM.Methods We retrospectively recruited patients with anti-SAE+DM in four tertiary referral centres from China between March 2005 and December 2022. Long-term survival analysis was performed on the enrolled patients. The Myositis Damage Index and Cutaneous Disease Area and Severity Index were used to evaluate the degree of different organ damage and the extent of skin rashes. Longitudinal CT patterns were analysed. Phenotypes were characterized using unsupervised cluster analysis.Results All-cause death occurred in 10.5% (4/38) of all patients, in which three patients succumbed to malignancies at 13, 18 and 36 months. Most patients had favourable long-term outcomes, 35.3% of them were in drug-free remission. Skin rashes showed significant improvement evaluated by Cutaneous Disease Area and Severity Index with time. However, damage to different systems was observed in 70.6% of the surviving patients using the Myositis Damage Index, which mainly consisted of skin damage, accounting for 47.1%. Nine patients with anti-SAE+DM-associated interstitial lung disease underwent repeat CT showed marked radiological improvement at 6 months or being stable after 12 months. In further, different characteristics and outcomes were also showed in three clusters identified by unsupervised analysis.Conclusions Anti-SAE+DM is characterized with a lower mortality rate and the development of malignancies being the primary cause of death. Patients who survived showed notable cutaneous damage, while the interstitial lung disease tends to stabilize. Clusters identified with unsupervised analysis could assist physicians in identifying a higher risk of mortality.
引用
收藏
页码:1377 / 1385
页数:9
相关论文
共 50 条
  • [31] Clinical manifestations, outcomes, and antibody profile of Brazilian adult patients with dermatomyositis: a single-center longitudinal study
    Carboni Truzzi, Natassia Cristina
    Hoff, Leonardo Santos
    Pires Borges, Isabela Bruna
    Carlos de Souza, Fernando Henrique
    Shinjo, Samuel Katsuyuki
    ADVANCES IN RHEUMATOLOGY, 2022, 62 (01)
  • [32] Multidisciplinary approach to anti-MDA5 antibody-positive dermatomyositis associated with rapidly progressive interstitial lung disease
    Witkowska, Anna Barbara
    Cowley, Sharon
    Dempsey, Philip
    Stack, John
    BMJ CASE REPORTS, 2022, 15 (03)
  • [33] Anti-MDA5 antibody-positive dermatomyositis with rapidly progressive interstitial lung disease: report of two cases
    Mehta, Asmita A.
    Paul, Tisa
    Cb, Mithun
    Haridas, Nithya
    BMJ CASE REPORTS, 2021, 14 (04)
  • [34] Changes in anti-MDA5 antibody titres and serum cytokine levels before and after diagnosis of anti-MDA5 antibody-positive dermatomyositis
    Kogami, Masahiro
    Abe, Yoshiyuki
    Ando, Taiki
    Makiyama, Ayako
    Yamaji, Ken
    Tamura, Naoto
    RHEUMATOLOGY, 2023, 62 (07) : 2525 - 2533
  • [35] Gender differences in patients with anti-MDA5-positive dermatomyositis: a cohort study of 251 cases
    Cheng, Lu
    Xu, Lingxiao
    Xu, Yan
    Yuan, Fenghong
    Li, Ju
    Wu, Min
    Da, Zhanyun
    Wei, Hua
    Zhou, Lei
    Yin, Songlou
    Wu, Jian
    Lu, Yan
    Su, Dinglei
    Liu, Zhichun
    Liu, Lin
    Ma, Longxin
    Xu, Xiaoyan
    Liu, Huijie
    Ren, Tianli
    Zang, Yinshan
    CLINICAL RHEUMATOLOGY, 2024, 43 (01) : 339 - 347
  • [36] Anti-MDA5 Antibody-Positive Clinically Amyopathic Dermatomyositis Associated With Multiple Heterologous Carcinomas: A Case Report
    Nakano, Yoshio
    Nishida, Koji
    Okamoto, Norio
    Gohma, Iwao
    Yasuhara, Yumiko
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (02)
  • [37] The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis
    Oldroyd, Alexander
    Sergeant, Jamie C.
    New, Paul
    McHugh, Neil J.
    Betteridge, Zoe
    Lamb, Janine A.
    Ollier, William E.
    Cooper, Robert G.
    Chinoy, Hector
    Ahmed, Yasmeen
    Armstrong, Raymond
    Bernstein, Robert
    Black, Carol
    Bowman, Simon
    Bruce, Ian
    Butler, Robin
    Carty, John
    Chattopadhyay, Chandra
    Chelliah, Easwaradhas
    Clarke, Fiona
    Dawes, Peter
    Devlin, Joseph
    Edwards, Christopher
    Emery, Paul
    Fordham, John
    Fraser, Alexander
    Gaston, Hill
    Gordon, Patrick
    Griffiths, Bridget
    Gunawardena, Harsha
    Hall, Frances
    Harrison, Beverley
    Hay, Elaine
    Horden, Lesley
    Isaacs, John
    Jones, Adrian
    Kamath, Sanjeet
    Kennedy, Thomas
    Kitas, George
    Klimiuk, Peter
    Knights, Sally
    Lambert, John
    Lanyon, Peter
    Laxminarayan, Ramasharan
    Lecky, Bryan
    Luqmani, Raashid
    Marks, Jeffrey
    Martin, Michael
    McGonagle, Dennis
    McHugh, Neil
    RHEUMATOLOGY, 2019, 58 (04) : 650 - 655
  • [38] Predictive factors for anti-MDA5 antibody in patients with dermatomyositis: a retrospective multicenter study
    Castellanos-Gonzalez, Maria
    Bris, Beatriz Butron
    Marsol, Isabel Bielsa
    Campos, Monica Munera
    Ruiz-Villaverde, Ricardo
    Llorente, Concha Postigo
    Nuno-Gonzalez, Almudena
    Sanchez, Jesus Tercedor
    Mur, Eva Chavarria
    Garcia, Rosa Gimenez
    Alonso, Ana Bauza
    Espanol, Gloria Aparicio
    Garcia, Yolanda Hidalgo
    Schmidt, Julia Maria Sanchez
    Sanchez, Manuel Almagro
    Crespo, Esther Roe
    de Las Heras Alonso, Elena
    Gallo-Pineda, Gonzalo
    Izquierdo, Jose Antonio Aviles
    Varillas-Delgado, David
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 (07): : 741 - 748
  • [39] Antimelanoma differentiation-associated gene 5 (anti-MDA5) antibody-positive dermatomyositis: clinical features and outcomes in a racially diverse patient cohort
    Koyoda, Sai K.
    Ezzy, Fatema
    Wahezi, Dawn
    Kumthekar, Anand
    Xie, Xianhong
    Tagoe, Clement E.
    Ayesha, Bibi
    BMC RHEUMATOLOGY, 2025, 9 (01)
  • [40] Incidence and impact of interstitial lung disease and malignancy in patients with polymyositis, dermatomyositis, and clinically amyopathic dermatomyositis: a retrospective cohort study
    Ikeda, Satoshi
    Arita, Machiko
    Misaki, Kenta
    Mishima, Shohei
    Takaiwa, Takuya
    Nishiyama, Akihiro
    Ito, Akihiro
    Furuta, Kenjiro
    Yokoyama, Toshihide
    Tokioka, Fumiaki
    Noyama, Maki
    Yoshioka, Hiroshige
    Ishida, Tadashi
    SPRINGERPLUS, 2015, 4